Market Size of Spine Biologics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Spine Biologics Market Analysis
The Spine Biologics Market is expected to register a CAGR of 4% during the forecast period. This is attributing to the growing geriatric population, rising prevalence of spine deformities, and technological advancements in bone grafting procedures. In addition, rising incidences of degenerative spine disorders with a significant increase in treatment rates and increasing preference for minimally invasive procedures are also fueling the growth of the market. Moreover, interbody fusion and direct lateral interbody fusion are the two advanced biological mechanisms for the treatment of the deformity of the spine and are highly adopted among surgeons globally. Furthermore, Advancements in the biomaterial and minimally invasive procedure approach associated with lateral body fusion is an ideal approach for the treatment of spine disorders as this procedure results in safe, effective, fast recovery and less injury. It further promotes the demand for spine biologics in the treatment of disc generation, sclerosis and other spine-related disorders. Spine injuries are very common among the population who are above 50 years as they are more susceptible to have structural alteration in the spine or spinal impairments thus growing geriatric population around worldwide will also promote the demand of treatment and diagnosis of the disorders. Therefore, the aforementioned factors will drive the spine biologics market in forecasted period.
Spine Biologics Industry Segmentation
As per the scope, Spine biologics comprises biomaterials that are used in the treatment of spinal cord injuries, degenerative disc diseases, and bone fusion surgeries. It mainly stimulates the growth of bone formation by different stages which involve inflammatory, repair, and remodeling. Spine Biologics Market is segmented By Product, End-User, and Geography.
| By Product | ||||
| ||||
| ||||
| Others |
| By End User | |
| Hospitals | |
| Ambulatory Surgical Centers | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Spine Biologics Market Size Summary
The Spine Biologics Market is poised for growth, driven by factors such as the increasing geriatric population, the rising prevalence of spine deformities, and advancements in bone grafting technologies. The market is experiencing a surge in demand due to the growing incidence of degenerative spine disorders and a shift towards minimally invasive procedures. Advanced biological mechanisms like interbody fusion and direct lateral interbody fusion are gaining traction among surgeons, enhancing the treatment of spine deformities. These procedures, along with advancements in biomaterials, offer safe and effective solutions with faster recovery times, thereby promoting the use of spine biologics for conditions such as disc degeneration and sclerosis. The susceptibility of individuals over 50 to spine injuries further amplifies the demand for treatment and diagnosis, positioning the market for significant growth during the forecast period.
Spinal allografts are expected to see robust growth due to their benefits, such as reducing surgery time and providing a scaffold for spine repair. Companies like Zimmer Biomet are leading the way in offering natural bone grafts, indicating a strong market demand for spinal allografts. North America is anticipated to hold a substantial market share, supported by a significant geriatric population, the adoption of minimally invasive procedures, and a high prevalence of spine disorders. The United States, in particular, is a key player in this region, with a large number of spinal cord injury cases driving the need for spine biologics. The market is moderately competitive, with major players like Johnson & Johnson, Orthofix Medical Inc., and Stryker Corporation dominating the landscape.
Spine Biologics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Growing Geriatric Population
-
1.2.2 Growing Prevalence of Spine Deformities
-
1.2.3 Technological Advancements
-
-
1.3 Market Restraints
-
1.3.1 Reimbursement Policies
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Product
-
2.1.1 Bone Graft Substitutes
-
2.1.1.1 Bone Morphogenetic Proteins
-
2.1.1.2 Synthetic Bone Grafts
-
-
2.1.2 Spinal Allografts
-
2.1.2.1 Machined Bones Allograft
-
2.1.2.2 Demineralized Bone Matrix
-
-
2.1.3 Others
-
-
2.2 By End User
-
2.2.1 Hospitals
-
2.2.2 Ambulatory Surgical Centers
-
2.2.3 Others
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Spine Biologics Market Size FAQs
What is the current Spine Biologics Market size?
The Spine Biologics Market is projected to register a CAGR of 4% during the forecast period (2024-2029)
Who are the key players in Spine Biologics Market?
Orthofix Medical Inc, Zimmer Biomet, Arthrex, Inc., Johnson & Johnson (Depuy Synthes) and Stryker Corporation are the major companies operating in the Spine Biologics Market.
